RCS - Brit Utd ProvAscBUPA - Bupa Announces Non-Executive Director Appointments

AlphabetAnnouncement

Today 10:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260331:nRSe8331Ya&default-theme=true

RNS Number : 8331Y  British Utd Provident Assoc (BUPA)  31 March 2026

Bupa appoints Philip Broadley, Bruno Holthof and Gill Whitehead as
Non-Executive Directors

 

31 March 2026

 

Bupa today announces the appointments of Philip Broadley as a Non-Executive
Director with effect from 1 April 2026 and Professor Bruno Holthof and Gill
Whitehead, OBE as Non-Executive Directors from 10 April 2026.

 

Philip will join the Audit, Risk and Remuneration Committees, Bruno will join
the Remuneration Committee and Gill will join the Risk Committee.  All three
will also join the Nomination & Governance Committee.

 

Philip brings extensive international life sciences and financial services
experience having worked in both senior executive and non-executive board
roles in four FTSE100 listed companies. Previously he was Group Finance
Director of Prudential plc from 2000 until 2008 and subsequently held the same
position at Old Mutual plc from 2008 until 2014. He has served as Chairman of
100 Group of Finance Directors and as a member of the Code Committee of The
Takeover Panel. He was a director of Legal & General Group plc from 2016
until 2025, chairing the audit committee for six years and serving for a time
as Senior Independent Director. Prior to his board roles, Mr. Broadley began
his career at Arthur Andersen in 1983, becoming a partner in 1993, where he
specialised in auditing banks and insurance companies. Mr. Broadley is a
Fellow of the Institute of Chartered Accountants in England and Wales. Mr.
Broadley graduated in Philosophy, Politics and Economics from St. Edmund Hall,
Oxford, where he is now a St. Edmund Fellow. He holds an MSc in Behavioural
Science from the London School of Economics. Philip is Chair of Lancashire
Holdings Limited and Senior Independent Director and Audit Committee Chair at
AstraZeneca PLC.

 

Bruno brings in-depth knowledge of healthcare systems in different markets,
with an operational understanding of healthcare services and more than 10
years' experience on the boards of public listed companies. He has previously
served as CEO of Oxford University Hospitals NHS Foundation Trust (2015-2022)
and CEO of the Antwerp Hospital Network (2004 - 2015).  Prior to that he was
a partner at McKinsey & Company, serving a wide range of healthcare
clients in Europe and the United States and gained significant expertise in
the areas of strategy, organisation and operations. He holds an MBA from the
Harvard Business School and an MD/PhD from the University of Leuven.  He is
Investment Partner of the EQT Life Sciences Health Economics Funds and
Visiting Professor of Health Innovation at the University of Oxford.
Non-Executive Chair of Financière de Tubize, reference shareholder of UCB, a
global biopharma company and Non-Executive Chair of Tristel plc, an AIM listed
company providing innovative disinfection solutions to hospitals worldwide.

 

Gill brings significant executive and regulatory experience in the technology
and media sectors having worked at Ofcom, Google, Channel 4 and the BBC. She
is a Visiting Policy Fellow at the University of Oxford's Internet Institute
focusing on global developments in AI safety, and is a Responsible AI
advisory panel member to UK Government Digital Services.  Gill was Group
Director, Online Safety at Ofcom until late 2024 and Chair of the Global
Online Safety Regulator Network for 2024. Before that, from 2021 to early
2023, she was Chief Executive of the Digital Regulators Forum, a collaboration
between the UK's largest regulators. Gill spent four years as a Senior
Director at Google, leading Market Insights and Client Solutions &
Analytics teams, after holding several digital strategy and data leadership
roles at Channel 4 and the BBC. She began her career at Deloitte Consulting.
Gill's Board experience spans FTSE 50 companies, public bodies and sport. She
has previously served as a Non-Executive Director of the Financial
Ombudsman Service and Camelot (operator of the UK National Lottery). She is
currently a Non-Executive Director at NatWest Group plc, Informa plc, the
British Olympic Association, and was Chair of the Women's Rugby World Cup
(England) 2025. She received an OBE in the 2026 King's New Year Honours for
services to women's rugby.

 

Don Robert, CBE, Bupa Board Chair said: "We are delighted to welcome Philip,
Bruno and Gill to the Bupa Board.  Their appointments will strengthen the
financial services, clinical and digital experience on the Board at an
important time in Bupa's strategic development, and I look forward to working
with them all."

 

 

The British United Provident Association Limited (BUPA 1025Z LN)

 ENDS 

About Bupa

Established in 1947, Bupa's purpose is helping people live longer, healthier,
happier lives and making a better world. We are an international healthcare
company serving 68 million customers worldwide. With no shareholders, we
reinvest profits into providing more and better healthcare for the benefit of
current and future customers. Bupa has businesses around the world,
principally in Australia, the UK, Spain, Poland, Chile, Hong Kong SAR, India,
Türkiye, Brazil, Mexico and New Zealand. We also have associate businesses in
Saudi Arabia.

 

For more information, visit bupa.com
(https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.bupa.com%2F&data=05%7C02%7CTracey.Crosier%40BUPA.com%7C6ff7bd8e92c9458aa9ae08dc1759fde1%7C02af5f5edd71405680903e7b436a65db%7C0%7C0%7C638410922490363515%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=vabIxk3%2BlJJgYop9249kIMxF9yc14flnTMW%2BBOHcyyg%3D&reserved=0)

 

Media contacts  external.relations@bupa.com
(mailto:external.relations@bupa.com)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAJBMRTMTAJMLF



            Copyright 2019 Regulatory News Service, all rights reserved